Organization
Institut du Cancer Paris CARPEM
5 abstracts
Abstract
REPROGRAM-02: A phase II-III study evaluating an induction treatment with regorafenib and metronomic chemotherapy before the second line chemotherapy in metastatic colorectal cancer.Org: University of Besançon, Etablissement Français du Sang Bourgogne Franche-Comté, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Hôpital Henri-Mondor, AP-HP - Université de Paris Est,
Abstract
Longitudinal circulating tumor DNA (ctDNA) analysis during treatment (Tx) of locally advanced resectable (LAR) gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ADENOCA): The PLAGAST prospective biomarker study.Org: Hôpital Européen Georges Pompidou, Université de Paris, Natera, Inc., Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Center de Recherche des Cordeliers,
Abstract
Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors.Org: Institut du Cancer Paris CARPEM, APHP-INSERM U1149 Universite Paris Diderot, Digestive Oncology Department, APHP.Centre - Université Paris Cité, Hôpital Européeen G. Pompidou,
Abstract
Immune features of ovarian tumors with a good response to neo-adjuvant chemotherapy in combination with an anti-PD-L1 alone or with an anti-CTLA4: Data from the randomized IneOV trial (a GINECO study).Org: Gustave-Roussy Cancer Campus, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Gustave Roussy Cancer Center, INSERM U981 GUSTAVE ROUSSY, Centre Catherine de Sienne,
Abstract
Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials.Org: Institut du Cancer Paris CARPEM, APHP-INSERM U1149 Universite Paris Diderot, APHP.Centre - Université Paris Cité, Université Paris Cité, Hôpital Européeen G. Pompidou,